APO Research
Talk to an analyst

APO RESEARCH · REPORT

Drugs for Transthyretin Amyloid Cardiomyopathy

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Drugs for Transthyretin Amyloid Cardiomyopathy Market Analysis and Forecast 2026-2032

27 December 2025198 pages

Choose your research edition.

Industry ResearchDrugs for Transthyretin Amyloid Cardiomyopathy Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Drugs for Transthyretin Amyloid Cardiomyopathy Industry Growth and Trends Forecast to 2032107 pages · $3,450 USDMarket StructureGlobal Drugs for Transthyretin Amyloid Cardiomyopathy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Drugs for Transthyretin Amyloid Cardiomyopathy Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Drugs for Transthyretin Amyloid Cardiomyopathy Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Drugs for Transthyretin Amyloid Cardiomyopathy market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Drugs for Transthyretin Amyloid Cardiomyopathy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Drugs for Transthyretin Amyloid Cardiomyopathy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Drugs for Transthyretin Amyloid Cardiomyopathy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Drugs for Transthyretin Amyloid Cardiomyopathy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Drugs for Transthyretin Amyloid Cardiomyopathy include Chia Tai Tianqing Pharmaceutical, Tonghua Zhongsheng Pharmaceutical, Zhengzhou Taifeng Pharmaceutical, Shapuaisi Pharma, Qilu pharmaceutical, Luoxin Pharmaceutical, Zydus Pharms, Teva and Pfizer, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Drugs for Transthyretin Amyloid Cardiomyopathy, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Drugs for Transthyretin Amyloid Cardiomyopathy, also provides the sales of main regions and countries. Of the upcoming market potential for Drugs for Transthyretin Amyloid Cardiomyopathy, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Drugs for Transthyretin Amyloid Cardiomyopathy sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Drugs for Transthyretin Amyloid Cardiomyopathy market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Drugs for Transthyretin Amyloid Cardiomyopathy sales, projected growth trends, production technology, application and end-user industry.

Drugs for Transthyretin Amyloid Cardiomyopathy Segment by Company

Chia Tai Tianqing Pharmaceutical

Tonghua Zhongsheng Pharmaceutical

Zhengzhou Taifeng Pharmaceutical

Shapuaisi Pharma

Qilu pharmaceutical

Luoxin Pharmaceutical

Zydus Pharms

Teva

Pfizer

Ionis Pharmaceuticals

Avet Pharmaceuticals

Alnylam Pharmaceuticals

Akcea Therapeutics

Drugs for Transthyretin Amyloid Cardiomyopathy Segment by Type

RNA Interference

Antisense Oligonucleotides

Transthyretin Tetramer Stabilizer

Other

Drugs for Transthyretin Amyloid Cardiomyopathy Segment by Application

Retail Pharmacies

Hospital and Clinic

Other

Drugs for Transthyretin Amyloid Cardiomyopathy Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drugs for Transthyretin Amyloid Cardiomyopathy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Drugs for Transthyretin Amyloid Cardiomyopathy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drugs for Transthyretin Amyloid Cardiomyopathy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Drugs for Transthyretin Amyloid Cardiomyopathy in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Drugs for Transthyretin Amyloid Cardiomyopathy manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Drugs for Transthyretin Amyloid Cardiomyopathy sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Drugs for Transthyretin Amyloid Cardiomyopathy Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. RNA Interference Major Manufacturers Table 3. Antisense Oligonucleotides Major Manufacturers Table 4. Transthyretin Tetramer Stabilizer Major Manufacturers Table 5. Other Major Manufacturers Table 6. Global Drugs for Transthyretin Amyloid Cardiomyopathy Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Retail Pharmacies Major Manufacturers Table 8. Hospital and Clinic Major Manufacturers Table 9. Other Major Manufacturers Table 10. Drugs for Transthyretin Amyloid Cardiomyopathy Industry Trends Table 11. Drugs for Transthyretin Amyloid Cardiomyopathy Industry Drivers Table 12. Drugs for Transthyretin Amyloid Cardiomyopathy Industry Opportunities and Challenges Table 13. Drugs for Transthyretin Amyloid Cardiomyopathy Industry Restraints Table 14. Global Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 15. Global Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Region (2021-2026) & (US$ Million) Table 16. Global Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Region (2027-2032) & (US$ Million) Table 17. Global Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Market Share by Region (2021-2026) Table 18. Global Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Market Share by Region (2027-2032) Table 19. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 20. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Region (2021-2026) & (K Units) Table 21. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Region (2027-2032) & (K Units) Table 22. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Market Share by Region (2021-2026) Table 23. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Market Share by Region (2027-2032) Table 24. Global Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Market Share by Manufacturers (2021-2026) Table 26. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Manufacturers (US$ Million) & (2021-2026) Table 27. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Market Share by Manufacturers (2021-2026) Table 28. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 29. Global Drugs for Transthyretin Amyloid Cardiomyopathy Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 30. Global Drugs for Transthyretin Amyloid Cardiomyopathy Key Manufacturers Manufacturing Sites & Headquarters Table 31. Global Drugs for Transthyretin Amyloid Cardiomyopathy Manufacturers, Product Type & Application Table 32. Global Drugs for Transthyretin Amyloid Cardiomyopathy Manufacturers' Establishment Date Table 33. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 34. Global Drugs for Transthyretin Amyloid Cardiomyopathy by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 35. Global Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Type (2021-2026) & (US$ Million) Table 37. Global Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Type (2027-2032) & (US$ Million) Table 38. Global Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Market Share by Type (2021-2026) Table 39. Global Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Market Share by Type (2027-2032) Table 40. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 41. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Type (2021-2026) & (K Units) Table 42. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Type (2027-2032) & (K Units) Table 43. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Market Share by Type (2021-2026) Table 44. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Market Share by Type (2027-2032) Table 45. Global Drugs for Transthyretin Amyloid Cardiomyopathy Price by Type (2021-2026) & (US$/Unit) Table 46. Global Drugs for Transthyretin Amyloid Cardiomyopathy Price by Type (2027-2032) & (US$/Unit) Table 47. Global Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Application (2021-2026) & (US$ Million) Table 49. Global Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Application (2027-2032) & (US$ Million) Table 50. Global Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Market Share by Application (2021-2026) Table 51. Global Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Market Share by Application (2027-2032) Table 52. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 53. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Application (2021-2026) & (K Units) Table 54. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Application (2027-2032) & (K Units) Table 55. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Market Share by Application (2021-2026) Table 56. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Market Share by Application (2027-2032) Table 57. Global Drugs for Transthyretin Amyloid Cardiomyopathy Price by Application (2021-2026) & (US$/Unit) Table 58. Global Drugs for Transthyretin Amyloid Cardiomyopathy Price by Application (2027-2032) & (US$/Unit) Table 59. Chia Tai Tianqing Pharmaceutical Company Information Table 60. Chia Tai Tianqing Pharmaceutical Business Overview Table 61. Chia Tai Tianqing Pharmaceutical Drugs for Transthyretin Amyloid Cardiomyopathy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 62. Chia Tai Tianqing Pharmaceutical Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolio Table 63. Chia Tai Tianqing Pharmaceutical Recent Development Table 64. Tonghua Zhongsheng Pharmaceutical Company Information Table 65. Tonghua Zhongsheng Pharmaceutical Business Overview Table 66. Tonghua Zhongsheng Pharmaceutical Drugs for Transthyretin Amyloid Cardiomyopathy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Tonghua Zhongsheng Pharmaceutical Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolio Table 68. Tonghua Zhongsheng Pharmaceutical Recent Development Table 69. Zhengzhou Taifeng Pharmaceutical Company Information Table 70. Zhengzhou Taifeng Pharmaceutical Business Overview Table 71. Zhengzhou Taifeng Pharmaceutical Drugs for Transthyretin Amyloid Cardiomyopathy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Zhengzhou Taifeng Pharmaceutical Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolio Table 73. Zhengzhou Taifeng Pharmaceutical Recent Development Table 74. Shapuaisi Pharma Company Information Table 75. Shapuaisi Pharma Business Overview Table 76. Shapuaisi Pharma Drugs for Transthyretin Amyloid Cardiomyopathy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Shapuaisi Pharma Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolio Table 78. Shapuaisi Pharma Recent Development Table 79. Qilu pharmaceutical Company Information Table 80. Qilu pharmaceutical Business Overview Table 81. Qilu pharmaceutical Drugs for Transthyretin Amyloid Cardiomyopathy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Qilu pharmaceutical Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolio Table 83. Qilu pharmaceutical Recent Development Table 84. Luoxin Pharmaceutical Company Information Table 85. Luoxin Pharmaceutical Business Overview Table 86. Luoxin Pharmaceutical Drugs for Transthyretin Amyloid Cardiomyopathy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Luoxin Pharmaceutical Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolio Table 88. Luoxin Pharmaceutical Recent Development Table 89. Zydus Pharms Company Information Table 90. Zydus Pharms Business Overview Table 91. Zydus Pharms Drugs for Transthyretin Amyloid Cardiomyopathy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Zydus Pharms Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolio Table 93. Zydus Pharms Recent Development Table 94. Teva Company Information Table 95. Teva Business Overview Table 96. Teva Drugs for Transthyretin Amyloid Cardiomyopathy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Teva Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolio Table 98. Teva Recent Development Table 99. Pfizer Company Information Table 100. Pfizer Business Overview Table 101. Pfizer Drugs for Transthyretin Amyloid Cardiomyopathy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Pfizer Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolio Table 103. Pfizer Recent Development Table 104. Ionis Pharmaceuticals Company Information Table 105. Ionis Pharmaceuticals Business Overview Table 106. Ionis Pharmaceuticals Drugs for Transthyretin Amyloid Cardiomyopathy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Ionis Pharmaceuticals Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolio Table 108. Ionis Pharmaceuticals Recent Development Table 109. Avet Pharmaceuticals Company Information Table 110. Avet Pharmaceuticals Business Overview Table 111. Avet Pharmaceuticals Drugs for Transthyretin Amyloid Cardiomyopathy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Avet Pharmaceuticals Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolio Table 113. Avet Pharmaceuticals Recent Development Table 114. Alnylam Pharmaceuticals Company Information Table 115. Alnylam Pharmaceuticals Business Overview Table 116. Alnylam Pharmaceuticals Drugs for Transthyretin Amyloid Cardiomyopathy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Alnylam Pharmaceuticals Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolio Table 118. Alnylam Pharmaceuticals Recent Development Table 119. Akcea Therapeutics Company Information Table 120. Akcea Therapeutics Business Overview Table 121. Akcea Therapeutics Drugs for Transthyretin Amyloid Cardiomyopathy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. Akcea Therapeutics Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolio Table 123. Akcea Therapeutics Recent Development Table 124. North America Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Type (2021-2026) & (US$ Million) Table 125. North America Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Type (2027-2032) & (US$ Million) Table 126. North America Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Type (2021-2026) & (K Units) Table 127. North America Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Type (2027-2032) & (K Units) Table 128. North America Drugs for Transthyretin Amyloid Cardiomyopathy Sales Price by Type (2021-2026) & (US$/Unit) Table 129. North America Drugs for Transthyretin Amyloid Cardiomyopathy Sales Price by Type (2027-2032) & (US$/Unit) Table 130. North America Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Application (2021-2026) & (US$ Million) Table 131. North America Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Application (2027-2032) & (US$ Million) Table 132. North America Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Application (2021-2026) & (K Units) Table 133. North America Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Application (2027-2032) & (K Units) Table 134. North America Drugs for Transthyretin Amyloid Cardiomyopathy Sales Price by Application (2021-2026) & (US$/Unit) Table 135. North America Drugs for Transthyretin Amyloid Cardiomyopathy Sales Price by Application (2027-2032) & (US$/Unit) Table 136. North America Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 137. North America Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 138. North America Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 139. North America Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 140. North America Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Country (2021-2026) & (K Units) Table 141. North America Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Country (2027-2032) & (K Units) Table 142. North America Drugs for Transthyretin Amyloid Cardiomyopathy Sales Price by Country (2021-2026) & (US$/Unit) Table 143. North America Drugs for Transthyretin Amyloid Cardiomyopathy Sales Price by Country (2027-2032) & (US$/Unit) Table 144. United States Drugs for Transthyretin Amyloid Cardiomyopathy Revenue (2021-2032) & (US$ Million) Table 145. Canada Drugs for Transthyretin Amyloid Cardiomyopathy Revenue (2021-2032) & (US$ Million) Table 146. Mexico Drugs for Transthyretin Amyloid Cardiomyopathy Revenue (2021-2032) & (US$ Million) Table 147. Europe Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Type (2021-2026) & (US$ Million) Table 148. Europe Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Type (2027-2032) & (US$ Million) Table 149. Europe Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Type (2021-2026) & (K Units) Table 150. Europe Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Type (2027-2032) & (K Units) Table 151. Europe Drugs for Transthyretin Amyloid Cardiomyopathy Sales Price by Type (2021-2026) & (US$/Unit) Table 152. Europe Drugs for Transthyretin Amyloid Cardiomyopathy Sales Price by Type (2027-2032) & (US$/Unit) Table 153. Europe Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Application (2021-2026) & (US$ Million) Table 154. Europe Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Application (2027-2032) & (US$ Million) Table 155. Europe Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Application (2021-2026) & (K Units) Table 156. Europe Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Application (2027-2032) & (K Units) Table 157. Europe Drugs for Transthyretin Amyloid Cardiomyopathy Sales Price by Application (2021-2026) & (US$/Unit) Table 158. Europe Drugs for Transthyretin Amyloid Cardiomyopathy Sales Price by Application (2027-2032) & (US$/Unit) Table 159. Europe Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 160. Europe Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 161. Europe Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 162. Europe Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 163. Europe Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Country (2021-2026) & (K Units) Table 164. Europe Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Country (2027-2032) & (K Units) Table 165. Europe Drugs for Transthyretin Amyloid Cardiomyopathy Sales Price by Country (2021-2026) & (US$/Unit) Table 166. Europe Drugs for Transthyretin Amyloid Cardiomyopathy Sales Price by Country (2027-2032) & (US$/Unit) Table 167. Germany Drugs for Transthyretin Amyloid Cardiomyopathy Revenue (2021-2032) & (US$ Million) Table 168. France Drugs for Transthyretin Amyloid Cardiomyopathy Revenue (2021-2032) & (US$ Million) Table 169. U.K. Drugs for Transthyretin Amyloid Cardiomyopathy Revenue (2021-2032) & (US$ Million) Table 170. Italy Drugs for Transthyretin Amyloid Cardiomyopathy Revenue (2021-2032) & (US$ Million) Table 171. Russia Drugs for Transthyretin Amyloid Cardiomyopathy Revenue (2021-2032) & (US$ Million) Table 172. Spain Drugs for Transthyretin Amyloid Cardiomyopathy Revenue (2021-2032) & (US$ Million) Table 173. Netherlands Drugs for Transthyretin Amyloid Cardiomyopathy Revenue (2021-2032) & (US$ Million) Table 174. Switzerland Drugs for Transthyretin Amyloid Cardiomyopathy Revenue (2021-2032) & (US$ Million) Table 175. Sweden Drugs for Transthyretin Amyloid Cardiomyopathy Revenue (2021-2032) & (US$ Million) Table 176. Poland Drugs for Transthyretin Amyloid Cardiomyopathy Revenue (2021-2032) & (US$ Million) Table 177. China Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Type (2021-2026) & (US$ Million) Table 178. China Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Type (2027-2032) & (US$ Million) Table 179. China Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Type (2021-2026) & (K Units) Table 180. China Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Type (2027-2032) & (K Units) Table 181. China Drugs for Transthyretin Amyloid Cardiomyopathy Sales Price by Type (2021-2026) & (US$/Unit) Table 182. China Drugs for Transthyretin Amyloid Cardiomyopathy Sales Price by Type (2027-2032) & (US$/Unit) Table 183. China Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Application (2021-2026) & (US$ Million) Table 184. China Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Application (2027-2032) & (US$ Million) Table 185. China Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Application (2021-2026) & (K Units) Table 186. China Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Application (2027-2032) & (K Units) Table 187. China Drugs for Transthyretin Amyloid Cardiomyopathy Sales Price by Application (2021-2026) & (US$/Unit) Table 188. China Drugs for Transthyretin Amyloid Cardiomyopathy Sales Price by Application (2027-2032) & (US$/Unit) Table 189. Asia Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Type (2021-2026) & (US$ Million) Table 190. Asia Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Type (2027-2032) & (US$ Million) Table 191. Asia Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Type (2021-2026) & (K Units) Table 192. Asia Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Type (2027-2032) & (K Units) Table 193. Asia Drugs for Transthyretin Amyloid Cardiomyopathy Sales Price by Type (2021-2026) & (US$/Unit) Table 194. Asia Drugs for Transthyretin Amyloid Cardiomyopathy Sales Price by Type (2027-2032) & (US$/Unit) Table 195. Asia Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Application (2021-2026) & (US$ Million) Table 196. Asia Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Application (2027-2032) & (US$ Million) Table 197. Asia Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Application (2021-2026) & (K Units) Table 198. Asia Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Application (2027-2032) & (K Units) Table 199. Asia Drugs for Transthyretin Amyloid Cardiomyopathy Sales Price by Application (2021-2026) & (US$/Unit) Table 200. Asia Drugs for Transthyretin Amyloid Cardiomyopathy Sales Price by Application (2027-2032) & (US$/Unit) Table 201. Asia Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 202. Asia Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 203. Asia Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 204. Asia Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 205. Asia Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Country (2021-2026) & (K Units) Table 206. Asia Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Country (2027-2032) & (K Units) Table 207. Asia Drugs for Transthyretin Amyloid Cardiomyopathy Sales Price by Country (2021-2026) & (US$/Unit) Table 208. Asia Drugs for Transthyretin Amyloid Cardiomyopathy Sales Price by Country (2027-2032) & (US$/Unit) Table 209. Japan Drugs for Transthyretin Amyloid Cardiomyopathy Revenue (2021-2032) & (US$ Million) Table 210. South Korea Drugs for Transthyretin Amyloid Cardiomyopathy Revenue (2021-2032) & (US$ Million) Table 211. India Drugs for Transthyretin Amyloid Cardiomyopathy Revenue (2021-2032) & (US$ Million) Table 212. Australia Drugs for Transthyretin Amyloid Cardiomyopathy Revenue (2021-2032) & (US$ Million) Table 213. Taiwan Drugs for Transthyretin Amyloid Cardiomyopathy Revenue (2021-2032) & (US$ Million) Table 214. Southeast Asia Drugs for Transthyretin Amyloid Cardiomyopathy Revenue (2021-2032) & (US$ Million) Table 215. SAMEA Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Type (2021-2026) & (US$ Million) Table 216. SAMEA Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Type (2027-2032) & (US$ Million) Table 217. SAMEA Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Type (2021-2026) & (K Units) Table 218. SAMEA Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Type (2027-2032) & (K Units) Table 219. SAMEA Drugs for Transthyretin Amyloid Cardiomyopathy Sales Price by Type (2021-2026) & (US$/Unit) Table 220. SAMEA Drugs for Transthyretin Amyloid Cardiomyopathy Sales Price by Type (2027-2032) & (US$/Unit) Table 221. SAMEA Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Application (2021-2026) & (US$ Million) Table 222. SAMEA Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Application (2027-2032) & (US$ Million) Table 223. SAMEA Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Application (2021-2026) & (K Units) Table 224. SAMEA Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Application (2027-2032) & (K Units) Table 225. SAMEA Drugs for Transthyretin Amyloid Cardiomyopathy Sales Price by Application (2021-2026) & (US$/Unit) Table 226. SAMEA Drugs for Transthyretin Amyloid Cardiomyopathy Sales Price by Application (2027-2032) & (US$/Unit) Table 227. SAMEA Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 228. SAMEA Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 229. SAMEA Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 230. SAMEA Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 231. SAMEA Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Country (2021-2026) & (K Units) Table 232. SAMEA Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Country (2027-2032) & (K Units) Table 233. SAMEA Drugs for Transthyretin Amyloid Cardiomyopathy Sales Price by Country (2021-2026) & (US$/Unit) Table 234. SAMEA Drugs for Transthyretin Amyloid Cardiomyopathy Sales Price by Country (2027-2032) & (US$/Unit) Table 235. Brazil Drugs for Transthyretin Amyloid Cardiomyopathy Revenue (2021-2032) & (US$ Million) Table 236. Argentina Drugs for Transthyretin Amyloid Cardiomyopathy Revenue (2021-2032) & (US$ Million) Table 237. Chile Drugs for Transthyretin Amyloid Cardiomyopathy Revenue (2021-2032) & (US$ Million) Table 238. Colombia Drugs for Transthyretin Amyloid Cardiomyopathy Revenue (2021-2032) & (US$ Million) Table 239. Peru Drugs for Transthyretin Amyloid Cardiomyopathy Revenue (2021-2032) & (US$ Million) Table 240. Saudi Arabia Drugs for Transthyretin Amyloid Cardiomyopathy Revenue (2021-2032) & (US$ Million) Table 241. Israel Drugs for Transthyretin Amyloid Cardiomyopathy Revenue (2021-2032) & (US$ Million) Table 242. UAE Drugs for Transthyretin Amyloid Cardiomyopathy Revenue (2021-2032) & (US$ Million) Table 243. Turkey Drugs for Transthyretin Amyloid Cardiomyopathy Revenue (2021-2032) & (US$ Million) Table 244. Iran Drugs for Transthyretin Amyloid Cardiomyopathy Revenue (2021-2032) & (US$ Million) Table 245. Egypt Drugs for Transthyretin Amyloid Cardiomyopathy Revenue (2021-2032) & (US$ Million) Table 246. Key Raw Materials Table 247. Raw Materials Key Suppliers Table 248. Drugs for Transthyretin Amyloid Cardiomyopathy Distributors List Table 249. Drugs for Transthyretin Amyloid Cardiomyopathy Customers List Table 250. Research Programs/Design for This Report Table 251. Authors List of This Report Table 252. Secondary Sources Table 253. Primary Sources List of Figures Figure 1. Drugs for Transthyretin Amyloid Cardiomyopathy Image Figure 2. Global Drugs for Transthyretin Amyloid Cardiomyopathy Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Drugs for Transthyretin Amyloid Cardiomyopathy Market Size Share 2021 VS 2025 VS 2032 Figure 4. RNA Interference Image Figure 5. Antisense Oligonucleotides Image Figure 6. Transthyretin Tetramer Stabilizer Image Figure 7. Other Image Figure 8. Global Drugs for Transthyretin Amyloid Cardiomyopathy Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Drugs for Transthyretin Amyloid Cardiomyopathy Market Size Share 2021 VS 2025 VS 2032 Figure 10. Retail Pharmacies Image Figure 11. Hospital and Clinic Image Figure 12. Other Image Figure 13. Global Drugs for Transthyretin Amyloid Cardiomyopathy Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Drugs for Transthyretin Amyloid Cardiomyopathy Revenue (2021-2032) & (US$ Million) Figure 15. Global Drugs for Transthyretin Amyloid Cardiomyopathy Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 16. Global Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Market Share by Region: 2025 Versus 2032 Figure 17. Global Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Market Share by Region (2021-2032) Figure 18. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales (2021-2032) & (K Units) Figure 19. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 20. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Market Share by Region (2021-2032) Figure 21. US & Canada & Mexico Drugs for Transthyretin Amyloid Cardiomyopathy Sales YoY (2021-2032) & (K Units) Figure 22. Europe Drugs for Transthyretin Amyloid Cardiomyopathy Sales YoY (2021-2032) & (K Units) Figure 23. China Drugs for Transthyretin Amyloid Cardiomyopathy Sales YoY (2021-2032) & (K Units) Figure 24. Asia (Excluding China) Drugs for Transthyretin Amyloid Cardiomyopathy Sales YoY (2021-2032) & (K Units) Figure 25. South America, Middle East and Africa Drugs for Transthyretin Amyloid Cardiomyopathy Sales YoY (2021-2032) & (K Units) Figure 26. Global Drugs for Transthyretin Amyloid Cardiomyopathy Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 27. Global Drugs for Transthyretin Amyloid Cardiomyopathy Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 28. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Global Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 30. Global Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 31. Global Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Market Share by Type (2021-2032) Figure 32. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 33. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 34. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Market Share by Type (2021-2032) Figure 35. Global Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 36. Global Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 37. Global Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Market Share by Application (2021-2032) Figure 38. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 39. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 40. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Market Share by Application (2021-2032) Figure 41. North America Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Share by Type (2021-2032) Figure 42. North America Drugs for Transthyretin Amyloid Cardiomyopathy Sales Share by Type (2021-2032) Figure 43. North America Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Share by Application (2021-2032) Figure 44. North America Drugs for Transthyretin Amyloid Cardiomyopathy Sales Share by Application (2021-2032) Figure 45. North America Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Share by Country (2021-2032) Figure 46. North America Drugs for Transthyretin Amyloid Cardiomyopathy Sales Share by Country (2021-2032) Figure 47. Europe Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Share by Type (2021-2032) Figure 48. Europe Drugs for Transthyretin Amyloid Cardiomyopathy Sales Share by Type (2021-2032) Figure 49. Europe Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Share by Application (2021-2032) Figure 50. Europe Drugs for Transthyretin Amyloid Cardiomyopathy Sales Share by Application (2021-2032) Figure 51. Europe Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Share by Country (2021-2032) Figure 52. Europe Drugs for Transthyretin Amyloid Cardiomyopathy Sales Share by Country (2021-2032) Figure 53. China Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Share by Type (2021-2032) Figure 54. China Drugs for Transthyretin Amyloid Cardiomyopathy Sales Share by Type (2021-2032) Figure 55. China Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Share by Application (2021-2032) Figure 56. China Drugs for Transthyretin Amyloid Cardiomyopathy Sales Share by Application (2021-2032) Figure 57. Asia Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Share by Type (2021-2032) Figure 58. Asia Drugs for Transthyretin Amyloid Cardiomyopathy Sales Share by Type (2021-2032) Figure 59. Asia Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Share by Application (2021-2032) Figure 60. Asia Drugs for Transthyretin Amyloid Cardiomyopathy Sales Share by Application (2021-2032) Figure 61. Asia Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Share by Country (2021-2032) Figur

Scope & coverage.

Types
  • RNA Interference
  • Antisense Oligonucleotides
  • Transthyretin Tetramer Stabilizer
  • Other
Applications
  • Retail Pharmacies
  • Hospital and Clinic
  • Other
Companies covered
  • Chia Tai Tianqing Pharmaceutical
  • Tonghua Zhongsheng Pharmaceutical
  • Zhengzhou Taifeng Pharmaceutical
  • Shapuaisi Pharma
  • Qilu pharmaceutical
  • Luoxin Pharmaceutical
  • Zydus Pharms
  • Teva
  • Pfizer
  • Ionis Pharmaceuticals
  • Avet Pharmaceuticals
  • Alnylam Pharmaceuticals
  • Akcea Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Drugs for Transthyretin Amyloid Cardiomyopathy Market by Type
  3. 1.2.1 Global Drugs for Transthyretin Amyloid Cardiomyopathy Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 RNA Interference
  5. 1.2.3 Antisense Oligonucleotides
  6. 1.2.4 Transthyretin Tetramer Stabilizer
  7. 1.2.5 Other
  8. 1.3 Drugs for Transthyretin Amyloid Cardiomyopathy Market by Application
  9. 1.3.1 Global Drugs for Transthyretin Amyloid Cardiomyopathy Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Retail Pharmacies
  11. 1.3.3 Hospital and Clinic
  12. 1.3.4 Other
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Drugs for Transthyretin Amyloid Cardiomyopathy Market Dynamics
  1. 2.1 Drugs for Transthyretin Amyloid Cardiomyopathy Industry Trends
  2. 2.2 Drugs for Transthyretin Amyloid Cardiomyopathy Industry Drivers
  3. 2.3 Drugs for Transthyretin Amyloid Cardiomyopathy Industry Opportunities and Challenges
  4. 2.4 Drugs for Transthyretin Amyloid Cardiomyopathy Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Region
  3. 3.2.1 Global Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Region (2021-2026)
  5. 3.2.3 Global Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Region (2027-2032)
  6. 3.2.4 Global Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Region
  9. 3.4.1 Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Region (2021-2026)
  11. 3.4.3 Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Region (2027-2032)
  12. 3.4.4 Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Manufacturers
  2. 4.1.1 Global Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Drugs for Transthyretin Amyloid Cardiomyopathy Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Manufacturers
  6. 4.2.1 Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Drugs for Transthyretin Amyloid Cardiomyopathy Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Drugs for Transthyretin Amyloid Cardiomyopathy Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Drugs for Transthyretin Amyloid Cardiomyopathy Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Drugs for Transthyretin Amyloid Cardiomyopathy Manufacturers, Product Type & Application
  13. 4.7 Global Drugs for Transthyretin Amyloid Cardiomyopathy Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Drugs for Transthyretin Amyloid Cardiomyopathy Market CR5 and HHI
  16. 4.8.2 2025 Drugs for Transthyretin Amyloid Cardiomyopathy Tier 1, Tier 2, and Tier 3
5 Drugs for Transthyretin Amyloid Cardiomyopathy Market by Type
  1. 5.1 Global Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Type
  2. 5.1.1 Global Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Type
  6. 5.2.1 Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Market Share by Type (2021-2032)
  9. 5.3 Global Drugs for Transthyretin Amyloid Cardiomyopathy Price by Type
6 Drugs for Transthyretin Amyloid Cardiomyopathy Market by Application
  1. 6.1 Global Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Application
  2. 6.1.1 Global Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Application
  6. 6.2.1 Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Market Share by Application (2021-2032)
  9. 6.3 Global Drugs for Transthyretin Amyloid Cardiomyopathy Price by Application
7 Company Profiles
  1. 7.1 Chia Tai Tianqing Pharmaceutical
  2. 7.1.1 Chia Tai Tianqing Pharmaceutical Company Information
  3. 7.1.2 Chia Tai Tianqing Pharmaceutical Business Overview
  4. 7.1.3 Chia Tai Tianqing Pharmaceutical Drugs for Transthyretin Amyloid Cardiomyopathy Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Chia Tai Tianqing Pharmaceutical Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolio
  6. 7.1.5 Chia Tai Tianqing Pharmaceutical Recent Developments
  7. 7.2 Tonghua Zhongsheng Pharmaceutical
  8. 7.2.1 Tonghua Zhongsheng Pharmaceutical Company Information
  9. 7.2.2 Tonghua Zhongsheng Pharmaceutical Business Overview
  10. 7.2.3 Tonghua Zhongsheng Pharmaceutical Drugs for Transthyretin Amyloid Cardiomyopathy Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Tonghua Zhongsheng Pharmaceutical Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolio
  12. 7.2.5 Tonghua Zhongsheng Pharmaceutical Recent Developments
  13. 7.3 Zhengzhou Taifeng Pharmaceutical
  14. 7.3.1 Zhengzhou Taifeng Pharmaceutical Company Information
  15. 7.3.2 Zhengzhou Taifeng Pharmaceutical Business Overview
  16. 7.3.3 Zhengzhou Taifeng Pharmaceutical Drugs for Transthyretin Amyloid Cardiomyopathy Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Zhengzhou Taifeng Pharmaceutical Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolio
  18. 7.3.5 Zhengzhou Taifeng Pharmaceutical Recent Developments
  19. 7.4 Shapuaisi Pharma
  20. 7.4.1 Shapuaisi Pharma Company Information
  21. 7.4.2 Shapuaisi Pharma Business Overview
  22. 7.4.3 Shapuaisi Pharma Drugs for Transthyretin Amyloid Cardiomyopathy Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Shapuaisi Pharma Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolio
  24. 7.4.5 Shapuaisi Pharma Recent Developments
  25. 7.5 Qilu pharmaceutical
  26. 7.5.1 Qilu pharmaceutical Company Information
  27. 7.5.2 Qilu pharmaceutical Business Overview
  28. 7.5.3 Qilu pharmaceutical Drugs for Transthyretin Amyloid Cardiomyopathy Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Qilu pharmaceutical Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolio
  30. 7.5.5 Qilu pharmaceutical Recent Developments
  31. 7.6 Luoxin Pharmaceutical
  32. 7.6.1 Luoxin Pharmaceutical Company Information
  33. 7.6.2 Luoxin Pharmaceutical Business Overview
  34. 7.6.3 Luoxin Pharmaceutical Drugs for Transthyretin Amyloid Cardiomyopathy Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Luoxin Pharmaceutical Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolio
  36. 7.6.5 Luoxin Pharmaceutical Recent Developments
  37. 7.7 Zydus Pharms
  38. 7.7.1 Zydus Pharms Company Information
  39. 7.7.2 Zydus Pharms Business Overview
  40. 7.7.3 Zydus Pharms Drugs for Transthyretin Amyloid Cardiomyopathy Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Zydus Pharms Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolio
  42. 7.7.5 Zydus Pharms Recent Developments
  43. 7.8 Teva
  44. 7.8.1 Teva Company Information
  45. 7.8.2 Teva Business Overview
  46. 7.8.3 Teva Drugs for Transthyretin Amyloid Cardiomyopathy Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Teva Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolio
  48. 7.8.5 Teva Recent Developments
  49. 7.9 Pfizer
  50. 7.9.1 Pfizer Company Information
  51. 7.9.2 Pfizer Business Overview
  52. 7.9.3 Pfizer Drugs for Transthyretin Amyloid Cardiomyopathy Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Pfizer Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolio
  54. 7.9.5 Pfizer Recent Developments
  55. 7.10 Ionis Pharmaceuticals
  56. 7.10.1 Ionis Pharmaceuticals Company Information
  57. 7.10.2 Ionis Pharmaceuticals Business Overview
  58. 7.10.3 Ionis Pharmaceuticals Drugs for Transthyretin Amyloid Cardiomyopathy Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Ionis Pharmaceuticals Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolio
  60. 7.10.5 Ionis Pharmaceuticals Recent Developments
  61. 7.11 Avet Pharmaceuticals
  62. 7.11.1 Avet Pharmaceuticals Company Information
  63. 7.11.2 Avet Pharmaceuticals Business Overview
  64. 7.11.3 Avet Pharmaceuticals Drugs for Transthyretin Amyloid Cardiomyopathy Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Avet Pharmaceuticals Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolio
  66. 7.11.5 Avet Pharmaceuticals Recent Developments
  67. 7.12 Alnylam Pharmaceuticals
  68. 7.12.1 Alnylam Pharmaceuticals Company Information
  69. 7.12.2 Alnylam Pharmaceuticals Business Overview
  70. 7.12.3 Alnylam Pharmaceuticals Drugs for Transthyretin Amyloid Cardiomyopathy Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Alnylam Pharmaceuticals Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolio
  72. 7.12.5 Alnylam Pharmaceuticals Recent Developments
  73. 7.13 Akcea Therapeutics
  74. 7.13.1 Akcea Therapeutics Company Information
  75. 7.13.2 Akcea Therapeutics Business Overview
  76. 7.13.3 Akcea Therapeutics Drugs for Transthyretin Amyloid Cardiomyopathy Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Akcea Therapeutics Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolio
  78. 7.13.5 Akcea Therapeutics Recent Developments
8 North America
  1. 8.1 North America Drugs for Transthyretin Amyloid Cardiomyopathy Market Size by Type
  2. 8.1.1 North America Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Type (2021-2032)
  3. 8.1.2 North America Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Type (2021-2032)
  4. 8.1.3 North America Drugs for Transthyretin Amyloid Cardiomyopathy Price by Type (2021-2032)
  5. 8.2 North America Drugs for Transthyretin Amyloid Cardiomyopathy Market Size by Application
  6. 8.2.1 North America Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Application (2021-2032)
  7. 8.2.2 North America Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Application (2021-2032)
  8. 8.2.3 North America Drugs for Transthyretin Amyloid Cardiomyopathy Price by Application (2021-2032)
  9. 8.3 North America Drugs for Transthyretin Amyloid Cardiomyopathy Market Size by Country
  10. 8.3.1 North America Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Drugs for Transthyretin Amyloid Cardiomyopathy Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Drugs for Transthyretin Amyloid Cardiomyopathy Market Size by Type
  2. 9.1.1 Europe Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Type (2021-2032)
  3. 9.1.2 Europe Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Type (2021-2032)
  4. 9.1.3 Europe Drugs for Transthyretin Amyloid Cardiomyopathy Price by Type (2021-2032)
  5. 9.2 Europe Drugs for Transthyretin Amyloid Cardiomyopathy Market Size by Application
  6. 9.2.1 Europe Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Application (2021-2032)
  7. 9.2.2 Europe Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Application (2021-2032)
  8. 9.2.3 Europe Drugs for Transthyretin Amyloid Cardiomyopathy Price by Application (2021-2032)
  9. 9.3 Europe Drugs for Transthyretin Amyloid Cardiomyopathy Market Size by Country
  10. 9.3.1 Europe Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Drugs for Transthyretin Amyloid Cardiomyopathy Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Drugs for Transthyretin Amyloid Cardiomyopathy Market Size by Type
  2. 10.1.1 China Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Type (2021-2032)
  3. 10.1.2 China Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Type (2021-2032)
  4. 10.1.3 China Drugs for Transthyretin Amyloid Cardiomyopathy Price by Type (2021-2032)
  5. 10.2 China Drugs for Transthyretin Amyloid Cardiomyopathy Market Size by Application
  6. 10.2.1 China Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Application (2021-2032)
  7. 10.2.2 China Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Application (2021-2032)
  8. 10.2.3 China Drugs for Transthyretin Amyloid Cardiomyopathy Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Drugs for Transthyretin Amyloid Cardiomyopathy Market Size by Type
  2. 11.1.1 Asia Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Type (2021-2032)
  3. 11.1.2 Asia Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Type (2021-2032)
  4. 11.1.3 Asia Drugs for Transthyretin Amyloid Cardiomyopathy Price by Type (2021-2032)
  5. 11.2 Asia Drugs for Transthyretin Amyloid Cardiomyopathy Market Size by Application
  6. 11.2.1 Asia Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Application (2021-2032)
  7. 11.2.2 Asia Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Application (2021-2032)
  8. 11.2.3 Asia Drugs for Transthyretin Amyloid Cardiomyopathy Price by Application (2021-2032)
  9. 11.3 Asia Drugs for Transthyretin Amyloid Cardiomyopathy Market Size by Country
  10. 11.3.1 Asia Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Drugs for Transthyretin Amyloid Cardiomyopathy Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Drugs for Transthyretin Amyloid Cardiomyopathy Market Size by Type
  2. 12.1.1 SAMEA Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Drugs for Transthyretin Amyloid Cardiomyopathy Price by Type (2021-2032)
  5. 12.2 SAMEA Drugs for Transthyretin Amyloid Cardiomyopathy Market Size by Application
  6. 12.2.1 SAMEA Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Drugs for Transthyretin Amyloid Cardiomyopathy Price by Application (2021-2032)
  9. 12.3 SAMEA Drugs for Transthyretin Amyloid Cardiomyopathy Market Size by Country
  10. 12.3.1 SAMEA Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Drugs for Transthyretin Amyloid Cardiomyopathy Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Drugs for Transthyretin Amyloid Cardiomyopathy Value Chain Analysis
  2. 13.1.1 Drugs for Transthyretin Amyloid Cardiomyopathy Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Drugs for Transthyretin Amyloid Cardiomyopathy Production Mode & Process
  6. 13.2 Drugs for Transthyretin Amyloid Cardiomyopathy Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Drugs for Transthyretin Amyloid Cardiomyopathy Distributors
  9. 13.2.3 Drugs for Transthyretin Amyloid Cardiomyopathy Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst